Onyx Pharmaceuticals Inc Watch

ended 06/30/13 Q2

ended 03/31/13 Q1

ended 12/31/12 FY 2012

ended 09/30/12 Q3

ended 06/30/12 Q2

Securities registration termination

Securities registration termination

Removal from listing

Amendment to registration of securities for employees

Amendment to registration of securities for employees

Cagnoni Pablo J

Wierenga Wendall

Shema Suzanne M

Wood Julianna R

Fust Matthew K

Material Definitive Agreement, Increase/Acceleration of Financial Obligation or Off-Balance Sheet Arrangement, Notice of Delisting, Failure to Satisfy Listing Rule, or Transfer of Listing, Material Modification to Rights of Security Holders, Change of Control, Change in Directors, Officers or Compensation, Amendment to Articles of Incorporation or Bylaws, or Change in Fiscal Year, Financial Statements or Exhibits

Re: Notice of Anticipated Make-Whole Fundamental Change

Amgen to Acquire Onyx Pharmaceuticals for $125 Per Share in Cash

Reports Second Quarter 2013 Financial Results

Earnings Release or Operating Update

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Confidential treatment order

Notice of effectiveness

Notice of effectiveness

Confidential treatment order

Confidential treatment order